UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowOppenheimer has increased the price target of UroGen Pharma (URGN) to $50, driven by positive sales outlook. This adjustment reflects expectations for future revenue growth and potential market performance. The revised target indicates increased confidence in UroGen's business trajectory. This news is significant for investors as it may influence stock performance and investor sentiment toward UroGen Pharma.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
